Screener
BioCryst Pharmaceuticals BCRX Current Debt
Current Debt at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityCurrent.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accrued expenses | 121,895 | 126,413 |
| Share-based liability | 16,360 | 13,743 |
| Operating lease liabilities | 1,912 | 317 |
| Finance lease liabilities | 1,092 | 1,312 |
| Royalty financing obligations | 43,808 | 38,455 |
| Deferred revenue | 12,320 | — |
| Total current liabilities | 208,846 | 196,066 |
| Operating lease liabilities | 10,603 | 8,571 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's current debt?
- BioCryst Pharmaceuticals (BCRX) reported current debt of $1.09M in Q2 2026.
- How has BioCryst Pharmaceuticals's current debt changed year-over-year?
- BioCryst Pharmaceuticals's current debt decreased by 32.4% year-over-year, from $1.62M to $1.09M.
- What is the long-term trend for BioCryst Pharmaceuticals's current debt?
- Over 4 years (2020 to 2025), BioCryst Pharmaceuticals's current debt has grown at a 2.7% compound annual growth rate (CAGR), from $1.18M to $1.31M.
- What does current debt mean?
- The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.
Ask your AI about BioCryst Pharmaceuticals's current debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude